Abstract
Membranous nephropathy (MN) is the most prevalent cause of primary nephrotic syndrome amongst the adult population. The conventional option of first-line treatment for MN is the Modified Ponticelli Regimen (MPR). Discovery of the phospholipase A2 receptor (PLA2R) as a target antigen in patients with MN has brought new perspective in the management of this disease. B-cell depleting agents such as Rituximab have emerged as a treatment option. There is considerable debate whether Rituximab should be favored over MPR, due to its superior safety profile.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
